SEC Form 4 · accession 0001232524-18-000154
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Treacy
Officer — SVP, Technical Operations
Period of report
Aug 10, 2018
Accepted (ET)
Aug 13, 2018 · 7:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2,F3 | Aug 10, 2018 | S | 1,309 | $176.6107 | D | 17,458 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.61 to $177.061. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Includes 126 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2018.